Association Between FIASMA Psychotropics and COVID-19

<p>What are FIASMA psychotropics? What do they have to do with COVID-19? In this episode, we discuss a recent study that compared rates of severe illness among patients who, when admitted for COVID-19, were or were not taking a FIASMA—a functional inhibitor of acid sphingomyelinase activity.</p> <p>Faculty: Jim Phelps, M.D.<br /> Host: Richard Seeber, M.D.</p> <ul> <li><strong><a href= "https://psychopharmacologyinstitute.com/cme-program?section=pricing&utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC196" target="_blank" rel="noopener">Learn more about our memberships here</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/publication/quick-take-vol-40-2658?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC196" target="_blank" rel="noopener">Earn 0.5 CMEs: Quick Take Vol. 40</a></strong></li> <li><strong><a href= "https://psychopharmacologyinstitute.com/section/association-between-fiasma-psychotropic-medications-and-reduced-risk-of-intubation-or-death-in-individuals-with-psychiatric-disorders-hospitalized-for-severe-covid-19-an-observational-multicenter-study-2658-5233?utm_source=Podcast&utm_medium=Podcast&utm_campaign=[Libsyn]OPC196" target="_blank" rel="noopener">Association Between FIASMA Psychotropic Medications and Reduced Risk of Intubation or Death in Individuals With Psychiatric Disorders Hospitalized for Severe COVID-19: An Observational Multicenter Study</a></strong></li> </ul>